<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Best Practice Series: Prostate Cancer &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/collections/diseasestate/bestpractice/bestpractice-prostatecancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Radiation for prostate cancer increases hip fracture risk</title>
		<link>http://www.thedoctorschannel.com/view/radiation-for-prostate-cancer-increases-hip-fracture-risk-2/</link>
		<pubDate>Fri, 01 Apr 2011 18:44:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Radiology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Urology]]></category>
		<category><![CDATA[Dr. Sean P. Elliott]]></category>
		<category><![CDATA[EBRT]]></category>
		<category><![CDATA[external-beam radiotherapy]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[radiation treatment]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/radiation-for-prostate-cancer-increases-hip-fracture-risk-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Men who receive radiation treatment for prostate cancer are at greater risk of hip fracture, a new study in the March 16 issue of Cancer reports. Based on the findings, men with prostate cancer considering their treatment options should be told about the risk associated with radiotherapy, especially if they -]]></description>
		
			<media:content duration="2:04" medium="video">
		<media:title><![CDATA[Radiation for prostate cancer increases hip fracture risk]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Men who receive radiation treatment for prostate cancer are at greater risk of hip fracture, a new study in the March 16 issue of Cancer reports. Based on the findings, men with prostate cancer considering their treatment options should be told about the risk associated with radiotherapy, especially if they -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/radiation-for-prostate-cancer-increases-hip-fracture-risk-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4224.jpg"/>
	<media:keywords><![CDATA[Dr. Sean P. Elliott,EBRT,external-beam radiotherapy,prostate cancer,radiation treatment,radiotherapy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Adjunctive Treatments for Castration Resistant Prostate Cancer</title>
		<link>http://www.thedoctorschannel.com/view/adjunctive-treatments-for-castration-resistant-prostate-cancer-2/</link>
		<pubDate>Tue, 29 Mar 2011 21:43:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Androgen]]></category>
		<category><![CDATA[androgen deprivation]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Ferrari]]></category>
		<category><![CDATA[FSH]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[NYU]]></category>
		<category><![CDATA[Penis]]></category>
		<category><![CDATA[prostate]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[prostatectomy]]></category>
		<category><![CDATA[Radical]]></category>
		<category><![CDATA[testosterone]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/adjunctive-treatments-for-castration-resistant-prostate-cancer-2/</guid>
		<description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the longstanding treatment options used in addition to chemotherapy, including antiadrogens and CYP inhibitors. Ketoconazole is an example of a CYP inhibitors. Related ReadingCYP17 inhibitors for prostate cancer therapy.Vasaitis TS, Bruno RD, Njar VC.J Steroid Biochem Mol Biol. 2010 Nov 17.]]></description>
		
			<media:content duration="2:03" medium="video">
		<media:title><![CDATA[Adjunctive Treatments for Castration Resistant Prostate Cancer]]></media:title>
	<media:description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the longstanding treatment options used in addition to chemotherapy, including antiadrogens and CYP inhibitors. Ketoconazole is an example of a CYP inhibitors. Related ReadingCYP17 inhibitors for prostate cancer therapy.Vasaitis TS, Bruno RD, Njar VC.J Steroid Biochem Mol Biol. 2010 Nov 17.]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/adjunctive-treatments-for-castration-resistant-prostate-cancer-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4211.jpg"/>
	<media:keywords><![CDATA[Androgen,androgen deprivation,cancer,Ferrari,FSH,LH,NYU,Penis,prostate,prostate cancer,prostatectomy,Radical,testosterone]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Intro to Treatment of Patients with Metastatic Prostate Cancer</title>
		<link>http://www.thedoctorschannel.com/view/intro-to-treatment-of-patients-with-metastatic-prostate-cancer-2/</link>
		<pubDate>Tue, 29 Mar 2011 21:38:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Ferrari]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[NYU]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Penis]]></category>
		<category><![CDATA[prostate]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[urology]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/intro-to-treatment-of-patients-with-metastatic-prostate-cancer-2/</guid>
		<description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses Androgen Deprivation Therapy. Androgen Deprivation Therapy is the gold standard for men with metastatic prostate cancer in addition to docetaxel based therapy. ADT typically instituted early and has been shown to delay the onset of complication of those with metastatic disease. -]]></description>
		
			<media:content duration="2:25" medium="video">
		<media:title><![CDATA[Intro to Treatment of Patients with Metastatic Prostate Cancer]]></media:title>
	<media:description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses Androgen Deprivation Therapy. Androgen Deprivation Therapy is the gold standard for men with metastatic prostate cancer in addition to docetaxel based therapy. ADT typically instituted early and has been shown to delay the onset of complication of those with metastatic disease. -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/intro-to-treatment-of-patients-with-metastatic-prostate-cancer-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4210.jpg"/>
	<media:keywords><![CDATA[cancer,chemotherapy,Ferrari,medicine,NYU,oncology,Penis,prostate,prostate cancer,PSA,urology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Men treated with Aggressive Therapy for Low Grade, Low Volume Prostate Cancer</title>
		<link>http://www.thedoctorschannel.com/view/men-treated-with-aggressive-therapy-for-low-grade-low-volume-prostate-cancer-2/</link>
		<pubDate>Tue, 29 Mar 2011 20:10:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Androgen]]></category>
		<category><![CDATA[androgen deprivation]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Ferrari]]></category>
		<category><![CDATA[FSH]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[NYU]]></category>
		<category><![CDATA[Penis]]></category>
		<category><![CDATA[prostate]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[prostatectomy]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[Radical]]></category>
		<category><![CDATA[testosterone]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/men-treated-with-aggressive-therapy-for-low-grade-low-volume-prostate-cancer-2/</guid>
		<description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses her experience with men who have been treated aggressively for low grade, low volume prostate cancer. There has been an estimate that a large proportion of these men could have done just as well with active surveillance. There are ongoing studies -]]></description>
		
			<media:content duration="2:29" medium="video">
		<media:title><![CDATA[Men treated with Aggressive Therapy for Low Grade, Low Volume Prostate Cancer]]></media:title>
	<media:description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses her experience with men who have been treated aggressively for low grade, low volume prostate cancer. There has been an estimate that a large proportion of these men could have done just as well with active surveillance. There are ongoing studies -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/men-treated-with-aggressive-therapy-for-low-grade-low-volume-prostate-cancer-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4206.jpg"/>
	<media:keywords><![CDATA[Androgen,androgen deprivation,cancer,Ferrari,FSH,LH,NYU,Penis,prostate,prostate cancer,prostatectomy,PSA,Radical,testosterone]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>A New Study of Taxotere with ADT as a Treatment for Prostate Cancer</title>
		<link>http://www.thedoctorschannel.com/view/a-new-study-of-taxotere-with-adt-as-a-treatment-for-prostate-cancer-2/</link>
		<pubDate>Tue, 29 Mar 2011 19:46:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Androgen]]></category>
		<category><![CDATA[androgen deprivation]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Ferrari]]></category>
		<category><![CDATA[FSH]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[NYU]]></category>
		<category><![CDATA[Penis]]></category>
		<category><![CDATA[prostate]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[prostatectomy]]></category>
		<category><![CDATA[Radical]]></category>
		<category><![CDATA[testosterone]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/a-new-study-of-taxotere-with-adt-as-a-treatment-for-prostate-cancer-2/</guid>
		<description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses new research led by the Eastern Cooperative Oncology group looking at a RCT of androgen deprivation therapy (ADT) vs ADT plus taxotere for 6 cycles. The rationale behind the trial is to look at the efficacy of chemotherapy in androgen dependent -]]></description>
		
			<media:content duration="2:06" medium="video">
		<media:title><![CDATA[A New Study of Taxotere with ADT as a Treatment for Prostate Cancer]]></media:title>
	<media:description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses new research led by the Eastern Cooperative Oncology group looking at a RCT of androgen deprivation therapy (ADT) vs ADT plus taxotere for 6 cycles. The rationale behind the trial is to look at the efficacy of chemotherapy in androgen dependent -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/a-new-study-of-taxotere-with-adt-as-a-treatment-for-prostate-cancer-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4205.jpg"/>
	<media:keywords><![CDATA[Androgen,androgen deprivation,cancer,Ferrari,FSH,LH,NYU,Penis,prostate,prostate cancer,prostatectomy,Radical,testosterone]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Radical Prostatectomy as a Treatment for Prostate Cancer</title>
		<link>http://www.thedoctorschannel.com/view/radical-prostatectomy-as-a-treatment-for-prostate-cancer-2/</link>
		<pubDate>Fri, 18 Mar 2011 23:40:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Davinci]]></category>
		<category><![CDATA[Ferrari]]></category>
		<category><![CDATA[NYU]]></category>
		<category><![CDATA[Penis]]></category>
		<category><![CDATA[prostate]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[prostatectomy]]></category>
		<category><![CDATA[Radical]]></category>
		<category><![CDATA[Robot]]></category>
		<category><![CDATA[Robotic]]></category>
		<category><![CDATA[surgery]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/radical-prostatectomy-as-a-treatment-for-prostate-cancer-2/</guid>
		<description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how radical prostatectomy can provide a definitive cure in many cases of prostate cancer. Advances in surgical techniques and the use of robotics are leading to less invasive surgeries with better outcomes for patients, including reduced impotence and incontinence.]]></description>
		
			<media:content duration="2:00" medium="video">
		<media:title><![CDATA[Radical Prostatectomy as a Treatment for Prostate Cancer]]></media:title>
	<media:description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how radical prostatectomy can provide a definitive cure in many cases of prostate cancer. Advances in surgical techniques and the use of robotics are leading to less invasive surgeries with better outcomes for patients, including reduced impotence and incontinence.]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/radical-prostatectomy-as-a-treatment-for-prostate-cancer-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4181.jpg"/>
	<media:keywords><![CDATA[cancer,Davinci,Ferrari,NYU,Penis,prostate,prostate cancer,prostatectomy,Radical,Robot,Robotic,surgery]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Prostate Cancer Requires a Multidisciplinary Approach</title>
		<link>http://www.thedoctorschannel.com/view/prostate-cancer-requires-a-multidisciplinary-approach-2/</link>
		<pubDate>Fri, 18 Mar 2011 23:12:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Anna Ferrari]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[NYU]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Penis]]></category>
		<category><![CDATA[prostate]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[urology]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/prostate-cancer-requires-a-multidisciplinary-approach-2/</guid>
		<description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how prostate cancer requires an integrated multidisciplinary approach. Related ReadingEnhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience.Gomella LG, Lin J, Hoffman-Censits J, Dugan P, Guiles F, Lallas CD, Singh J, McCue P, Showalter T, Valicenti RK, Dicker -]]></description>
		
			<media:content duration="1:56" medium="video">
		<media:title><![CDATA[Prostate Cancer Requires a Multidisciplinary Approach]]></media:title>
	<media:description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how prostate cancer requires an integrated multidisciplinary approach. Related ReadingEnhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience.Gomella LG, Lin J, Hoffman-Censits J, Dugan P, Guiles F, Lallas CD, Singh J, McCue P, Showalter T, Valicenti RK, Dicker -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/prostate-cancer-requires-a-multidisciplinary-approach-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4179.jpg"/>
	<media:keywords><![CDATA[Anna Ferrari,cancer,MD,medicine,NYU,oncology,Penis,prostate,prostate cancer,urology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Diagnosing Prostate Cancer</title>
		<link>http://www.thedoctorschannel.com/view/diagnosing-prostate-cancer-2/</link>
		<pubDate>Tue, 15 Mar 2011 19:53:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Anna Ferrari]]></category>
		<category><![CDATA[Gleason score]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[tumor size]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/diagnosing-prostate-cancer-2/</guid>
		<description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the diagnosis of prostate cancer and what a man needs to know. The three most important things are cancer size, PSA level and Gleason score. Related ReadingAssociation of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality.Pomerantz M, Werner -]]></description>
		
			<media:content duration="2:08" medium="video">
		<media:title><![CDATA[Diagnosing Prostate Cancer]]></media:title>
	<media:description><![CDATA[Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the diagnosis of prostate cancer and what a man needs to know. The three most important things are cancer size, PSA level and Gleason score. Related ReadingAssociation of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality.Pomerantz M, Werner -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/diagnosing-prostate-cancer-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4165.jpg"/>
	<media:keywords><![CDATA[Anna Ferrari,Gleason score,MD,prostate cancer,tumor size]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Brachytherapy good option for younger prostate cancer patients</title>
		<link>http://www.thedoctorschannel.com/view/brachytherapy-good-option-for-younger-prostate-cancer-patients-2/</link>
		<pubDate>Fri, 10 Dec 2010 00:31:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Urology]]></category>
		<category><![CDATA[BJUI]]></category>
		<category><![CDATA[Brachytherapy]]></category>
		<category><![CDATA[Dr. Karel A. Hinnen]]></category>
		<category><![CDATA[external-beam radiotherapy]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[prostatectomy]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/brachytherapy-good-option-for-younger-prostate-cancer-patients-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Brachytherapy is a viable option for prostate cancer patients 60 and younger, the authors of a new report in BJUI conclude. “Prostate cancer brachytherapy delivers excellent results in patients with early stage prostate cancer irrespective of their age,” Dr. Karel A. Hinnen of the University Medical Center Utrecht in The -]]></description>
		
			<media:content duration="1:47" medium="video">
		<media:title><![CDATA[Brachytherapy good option for younger prostate cancer patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Brachytherapy is a viable option for prostate cancer patients 60 and younger, the authors of a new report in BJUI conclude. “Prostate cancer brachytherapy delivers excellent results in patients with early stage prostate cancer irrespective of their age,” Dr. Karel A. Hinnen of the University Medical Center Utrecht in The -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/brachytherapy-good-option-for-younger-prostate-cancer-patients-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3928.jpg"/>
	<media:keywords><![CDATA[BJUI,Brachytherapy,Dr. Karel A. Hinnen,external-beam radiotherapy,prostate cancer,prostatectomy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Time to reconsider what insignificant prostate cancer is?</title>
		<link>http://www.thedoctorschannel.com/view/time-to-reconsider-what-insignificant-prostate-cancer-is-2/</link>
		<pubDate>Thu, 02 Dec 2010 02:18:00 +0000</pubDate> 
				<category><![CDATA[Best Practice Series: Prostate Cancer]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Urology]]></category>
		<category><![CDATA[Journal of Urology]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/time-to-reconsider-what-insignificant-prostate-cancer-is-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The tumor volume threshold of 0.5 mL for clinically insignificant prostate cancer, established in the early 1990s, remains valid, according to researchers who revisited this cut point in a contemporary group of prostate cancer patients. But the study also suggests that clinically insignificant prostate cancer may include an index Gleason -]]></description>
		
			<media:content duration="1:35" medium="video">
		<media:title><![CDATA[Time to reconsider what insignificant prostate cancer is?]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The tumor volume threshold of 0.5 mL for clinically insignificant prostate cancer, established in the early 1990s, remains valid, according to researchers who revisited this cut point in a contemporary group of prostate cancer patients. But the study also suggests that clinically insignificant prostate cancer may include an index Gleason -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/time-to-reconsider-what-insignificant-prostate-cancer-is-2/collection/collection-bestpractice-prostatecancer" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3894.jpg"/>
	<media:keywords><![CDATA[Journal of Urology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
